B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

BACKGROUND There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and depletes CD20+ B lymphocytes. METHODS In a phase 2, double-blind, 48-week trial involving 104 patients with relapsing-remitting multiple sclerosis, we assigned 69 patients to receive 1000 mg of intravenous rituximab and 35 patients to receive placebo on days 1 and 15. The primary end point was the total count of gadolinium-enhancing lesions detected on magnetic resonance imaging scans of the brain at weeks 12, 16, 20, and 24. Clinical outcomes included safety, the proportion of patients who had relapses, and the annualized rate of relapse. RESULTS As compared with patients who received placebo, patients who received rituximab had reduced counts of total gadolinium-enhancing lesions at weeks 12, 16, 20, and 24 (P<0.001) and of total new gadolinium-enhancing lesions over the same period (P<0.001); these results were sustained for 48 weeks (P<0.001). As compared with patients in the placebo group, the proportion of patients in the rituximab group with relapses was significantly reduced at week 24 (14.5% vs. 34.3%, P=0.02) and week 48 (20.3% vs. 40.0%, P=0.04). More patients in the rituximab group than in the placebo group had adverse events within 24 hours after the first infusion, most of which were mild-to-moderate events; after the second infusion, the numbers of events were similar in the two groups. CONCLUSIONS A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to assess long-term safety or to detect uncommon adverse events. The data provide evidence of B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis. (ClinicalTrials.gov number, NCT00097188 [ClinicalTrials.gov].).

[1]  R. De Palma,et al.  Rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[2]  F. Breedveld,et al.  Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response , 2007, Journal of clinical pharmacology.

[3]  M. Duddy,et al.  Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis , 2007, The Journal of Immunology.

[4]  M. Trojano,et al.  New natural history of interferon‐β–treated relapsing multiple sclerosis , 2007 .

[5]  P. Narayana,et al.  Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial , 2007, Annals of neurology.

[6]  M. Trojano,et al.  New natural history of interferon-beta-treated relapsing multiple sclerosis. , 2007, Annals of neurology.

[7]  R. Reynolds,et al.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.

[8]  M. Duddy,et al.  B-cells in multiple sclerosis. , 2006, International MS journal.

[9]  H. Link,et al.  Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.

[10]  S. Hauser,et al.  The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration , 2006, Neuron.

[11]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[12]  M. Krumbholz,et al.  B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation , 2006, Annals of neurology.

[13]  J. Bennett,et al.  The B cell response in multiple sclerosis , 2006, Neurological research.

[14]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[15]  W. Robinson,et al.  Lipid microarrays identify key mediators of autoimmune brain inflammation , 2006, Nature Medicine.

[16]  R. Sobel,et al.  Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions , 2005, Journal of Neuroimmunology.

[17]  D. Hafler,et al.  Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein1 , 2005, The Journal of Immunology.

[18]  A. Uccelli,et al.  Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Å. Sidén.  Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS , 1979, Journal of Neurology.

[20]  A. Bar-Or,et al.  Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions , 2003, Journal of Neuroimmunology.

[21]  K. Digre.  McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. , 2002 .

[22]  Freddy Ståhlberg,et al.  Combined diffusion weighting and CSF suppression in functional MRI , 2002, NMR in biomedicine.

[23]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[24]  E. E. Max,et al.  All about B Cells , 2001 .

[25]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[26]  D. Gilden,et al.  Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response , 2000, Neurology.

[27]  N. Chiorazzi,et al.  Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients1 , 2000, The Journal of Immunology.

[28]  S. Baranzini,et al.  B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. , 1999, Journal of immunology.

[29]  V. Diehl,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .

[30]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[31]  S. Hauser,et al.  Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.

[32]  D. Gilden,et al.  Restricted use of VH4 Germline segments in an acute multiple sclerosis brain , 1998, Annals of neurology.

[33]  D. R. Anderson,et al.  Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. , 1997, Biochemical Society transactions.

[34]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[35]  J. W. Rose,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.

[36]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[37]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[38]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.